Roflumilast Market

Roflumilast Market Size, Share & Industry Analysis, By Source (Petroleum-Based, Bio-Based), By End-User (Pharmaceuticals & Healthcare, Food & Beverage, Cosmetics & Skincare, Chemical & Polymer Industry), and Forecast Period 2025-2035

The Roflumilast market is projected to grow at a CAGR of 6.2% from 2025 to 2035, driven by the rising global burden of chronic obstructive pulmonary disease (COPD), increasing awareness of anti-inflammatory therapies for pulmonary care, and expanding applications in asthma and other inflammatory airway conditions. Roflumilast is an oral selective phosphodiesterase-4 (PDE4) inhibitor, which reduces inflammation by elevating intracellular cyclic AMP (cAMP) levels in lung tissues, thereby inhibiting the release of pro-inflammatory mediators.

Roflumilast is primarily indicated as an add-on therapy to bronchodilators in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Its anti-inflammatory mechanism addresses a key pathological component of COPD, particularly in patients with frequent exacerbations despite optimized inhaler use. Growing evidence of its utility in asthma, cystic fibrosis, and other inflammatory respiratory disorders is supporting its potential off-label expansion. Additionally, the shift towards oral maintenance therapies in chronic pulmonary conditions enhances its market appeal.

North America holds a dominant market share due to high disease prevalence, greater adoption of novel anti-inflammatory agents, and favorable reimbursement frameworks. Europe follows closely with strong clinical guidelines supporting PDE4 inhibitors. The Asia-Pacific region is projected to grow the fastest, driven by rising smoking rates, air pollution, and increasing diagnosis of COPD in aging populations. Latin America and Africa show moderate growth, supported by public health efforts and improved access to pulmonary care.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Roflumilast
Key End-Users & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Demand-Supply Dynamics

Segmental Outlook

By Source
Branded Roflumilast (e.g., Daliresp, Daxas)
Generic Roflumilast
Key End-Use Industries
Ophthalmology Clinics
Hospitals
Retail Pharmacies
Online Pharmacies

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Trade Analysis

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, and Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Production Capacity
Company Profiles & Key Developments
Interquim SA (Spain)
Inke S.A. (Spain)
LGM Pharma (USA)
HRV Global Life Sciences (India)
M2i Group (France)
Beijing Mesochem Technology (China)
Alivus Life Sciences (India)
ALP Pharm (China)
Aspire Lifesciences Pvt Ltd (India)
Aurobindo Pharma Limited (India)
CHEMO (Spain)
Chongqing Huapont Pharmaceutical (China)
DEAFARMA (Italy)
Glenmark Pharmaceuticals (India)
Hetero Drugs (India)
Hunan Huateng Pharmaceutical Co. Ltd. (China)
Lee Pharma (India)
MSN Laboratories (India)
ScinoPharm Taiwan Ltd. (Taiwan)
Zydus Lifesciences (India)

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 28, 2025

What is Roflumilast?

Roflumilast is an oral phosphodiesterase-4 (PDE4) inhibitor primarily used for the treatment of chronic obstructive pulmonary disease (COPD), particularly in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It works by selectively inhibiting the PDE4 enzyme, which plays a key role in the inflammatory process. By reducing inflammation in the lungs, Roflumilast helps decrease the frequency and severity of COPD flare-ups. Unlike bronchodilators, which target airway constriction, Roflumilast acts systemically to address the underlying inflammation, making it a complementary therapy rather than a first-line treatment. It is typically prescribed alongside bronchodilators in patients with more advanced COPD.

What is the market growth of Roflumilast?

The global Roflumilast market is expected to grow at a CAGR of 6.2% from 2025 to 2035, increasing from approximately USD 550 million in 2025 to nearly USD 1 billion by 2035. This growth is fueled by the rising global prevalence of COPD, driven by aging populations, increased tobacco use, and growing exposure to environmental pollutants. The need for effective long-term anti-inflammatory therapies for COPD patients is expected to support continued demand for Roflumilast, especially in regions with high disease burden. Moreover, growing awareness about COPD management and improved diagnostic capabilities are contributing to increased treatment rates.

What are the drivers of the Roflumilast market?

Key drivers of the Roflumilast market include the increasing prevalence of COPD and other chronic inflammatory respiratory diseases, the rising global elderly population, and the growing adoption of anti-inflammatory therapies in COPD treatment regimens. The limitations of current bronchodilators in controlling inflammation highlight the need for adjunctive therapies like Roflumilast. In addition, continued investment in respiratory disease management and the development of fixed-dose combinations involving Roflumilast and bronchodilators are likely to further support market growth. Increased healthcare awareness and improved access to care in developing economies also contribute to market expansion.

Who are the key players operating in the Roflumilast market?

The key players in the Roflumilast market include AstraZeneca, which markets the drug under the brand name Daliresp in the United States, and Takeda Pharmaceutical, which also has a strong presence in Asian markets. Other significant players include Teva Pharmaceuticals, Cipla, and Mylan, which manufacture generic formulations of Roflumilast. These companies are actively involved in expanding market reach through partnerships, generic production, and the development of combination therapies to improve treatment outcomes and accessibility.

Which region will exhibit the fastest growth in the Roflumilast market?

The Asia-Pacific region is projected to exhibit the fastest growth in the Roflumilast market due to rising COPD prevalence, expanding healthcare infrastructure, and increased smoking rates in countries like China and India. Meanwhile, North America remains the largest market due to widespread diagnosis and treatment of COPD, strong pharmaceutical R&D, and established reimbursement systems. Europe also maintains a significant share, especially in Western European nations with advanced healthcare systems and aging populations. Efforts to promote early diagnosis and effective management of COPD are expected to drive sustained demand across these key regions.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com